TY - JOUR
T1 - Antiplatelet therapy and cardiovascular primary prevention: influence of gender, age and other risk factors.
AU - Sousa, Maria Catarina Carapinha Salvado
AU - Clara, João Pedro Pereira Gorjão
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.
AB - Intervention for cardiovascular primary prevention has shown promising results in several trials. Studies performed up to 2002 showed a significant effect of aspirin in primary prevention of ischemic heart disease, with a significant reduction in non-fatal acute myocardial infarction, especially in men. Since then, new evidence has demonstrated the potential effect of antiplatelet therapy in cardiovascular primary prevention, particularly in less represented subgroups. In this article, we review the main studies on antiplatelet therapy and cardiovascular primary prevention, highlighting the results for these subgroups in terms of gender, age and presence of diabetes, chronic renal failure or atrial fibrillation, and then propose some clinical guidelines.
M3 - Article
C2 - 18605070
SN - 0870-2551
VL - 27
SP - 513
EP - 527
JO - Revista Portuguesa de Cardiologia
JF - Revista Portuguesa de Cardiologia
IS - 4
ER -